September 4, 2023 – Page 4

US Pharmacy Market Size to Surpass USD 861.67 Billion by 2028, exhibiting a CAGR of 6.3%

Written by Customer Service on September 4, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the global US pharmacy market size is projected to reach USD 861.67 Billion in 2028, at a CAGR of 6.3% during the forecast period, 2021-2028 US Pharmacy Market US Pharmacy Market (2021-2028) Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) — The U.S. pharmacy market is projected to grow from USD 560.00 billion in 2021 to USD 861.67 billion by 2028 at a CAGR of 6.3% during the forecast period 2021-2028. Surging occurrence of aliments in U.S., and rising healthcare spending are few of the prime aspects fueling the growth of pharmaceuticals market. This information is published by Fortune Business Insights™, in its report, titled, “U.S. Pharmacy Market, 2021-2028.” Key Takeaways: The increasing penetration and literacy regarding internet usage are anticipated to boost the...

Tokenization Market Size to Surpass USD 9.82 Billion by 2030, exhibiting a CAGR of 19.6%

Written by Customer Service on September 4, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the Tokenization Market size is projected to reach USD 9.82 Billion in 2030, at a CAGR of 19.6% during the forecast period, 2023-2030 Tokenization Market Forecast, 2023 – 2030 Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) — The global tokenization market size was valued at USD 2.39 billion in 2022 and is projected to reach USD 9.82 billion by 2030, exhibiting a CAGR of 19.6% during the forecast period. Fortune Business Insights has presented this information in their latest report titled “Global Tokenization Market Forecast, 2023-2030.” Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/tokenization-market-107201 Tokenization is a process where sensitive and important data is transformed by unique identifying symbols, which retain...

Brain Tumor Drugs Market Size to Surpass USD 3.72 Billion in 2030, exhibiting a CAGR of 10.2%

Written by Customer Service on September 4, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, The global Brain tumor drugs market size was valued at USD 1.80 billion in 2022. The market is projected to expand from USD 1.89 billion in 2023 to USD 3.72 billion by 2030, exhibiting a CAGR of 10.2% over the estimated period. Brain Tumor Drug Market Forecast 2023-2030 Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) — The global Brain tumor drugs market size was valued at USD 1.80 billion in 2022 and is projected to USD 3.72 billion by 2030, exhibiting a CAGR of 10.2% over estimated period. The rise is driven by the increasing aging population and the growing prevalence of smoking. Fortune Business Insights™ provides this information in its research report, titled “Brain Tumor Drugs Market, 2023-2030”. Key Industry Development: June 2022 – Novartis secured the approval...

Recombinant DNA Technology Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand, and Forecast

Written by Customer Service on September 4, 2023. Posted in Mergers And Acquisitions.

Companies Profiled in the Recombinant DNA Technology Market Are Novartis AG, Thermo Fisher Scientific Inc., Sanofi Pasteur Limited, Merck KGaA, Genentech Inc., GlaxoSmithKline plc., Eli Lilly and Company, Pfizer Inc., Janssen Pharmaceuticals Inc., and others. Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) — The global recombinant DNA technology market is expected to grow during 2023 to 2030. The growth of the market is driven by the increasing demand for recombinant DNA-based products and services in the healthcare, agricultural, and industrial sectors. The global recombinant DNA technology market will grow considerably in the coming years due to exceptional scientific advancements in gene therapy. The development of recombinant DNA (rDNA) technology has given researchers unprecedented control over genetic information. Recombinant...

Form 8.3 – [EMIS Group plc – 01 09 2023] – (CGWL)

Written by Customer Service on September 4, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing...

Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

Written by Customer Service on September 4, 2023. Posted in Public Companies.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. SEPTEMBER 4, 2023 On December 12, 2022, Novozymes A/S (“Novozymes”) and Chr. Hansen Holding A/S (“Chr. Hansen”) announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Reference is made to Chr. Hansen’s company announcement no. 13 of December 12, 2022. The Chinese State Administration for Market Regulation (SAMR) has now unconditionally approved the statutory merger of Novozymes and Chr. Hansen. The approval by SAMR was a condition to completion of the combination. The completion of...

Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

Written by Customer Service on September 4, 2023. Posted in Public Companies.

Please read the announcement in PDF Attachment 2023_Chinese_merger_approval_granted

Hywin Holdings to Announce Second Half and Fiscal Year 2023 Financial Results on September 15, 2023

Written by Customer Service on September 4, 2023. Posted in Public Companies.

SHANGHAI, China, Sept. 04, 2023 (GLOBE NEWSWIRE) — Hywin Holdings Ltd. (“Hywin,” or the “Company”) (NASDAQ: HYW), a leading independent wealth management service provider in China, today announced that it plans to report its unaudited financial results for the second half and fiscal year 2023 ended June 30, 2023, before the market opens on Friday, September 15, 2023. Hywin’s management will hold a conference call on Friday, September 15, 2023 at 8:00 A.M. Eastern Time (8:00 P.M. Beijing Time on the same day) to discuss the financial results. Details for the conference call are as follows: Event Title: Hywin Holdings Ltd. Second Half and Fiscal Year 2023 Earnings Conference CallRegistration Link: https://s1.c-conf.com/diamondpass/10033171-5zce7p.html All participants must use the link provided above to complete the online registration...

RCI Banque: 2023 Half-yearly Financial Report is now available

Written by Customer Service on September 4, 2023. Posted in Earnings Releases And Operating Results.

September 4th, 2023 RCI Banque: 2023 Half-yearly Financial Report is now available The RCI Banque group “Half-year Financial Report 2023” is now available on the website www.mobilize-fs.com RCI Banque S.A. French credit institution and insurance brokerage company, with a capital of 100,000,000 EUR Head office: 15 rue d’Uzès – 75002 PARIS SIREN : 306 523 358 R.C.S. Paris – VAT N°: FR95 306523358 – APE code: 6419Z – ORIAS N°: 07 023 704 – www.orias.frMobilize Financial Services is a trademark operated by RCI Banque S.A. Attachment RAPPORT FINANCIER SEMESTRIEL RCI 30-06-2023 ENG

RCI Banque: the “EMTN Semi-Annual Report 2023” is now available

Written by Customer Service on September 4, 2023. Posted in Earnings Releases And Operating Results.

September 4th, 2023 RCI Banque: The EMTN Semi-Annual Report 2023 is now available The RCI Banque group “The EMTN Semi-Annual Report 2023” is now available on the website www.mobilize-fs.com RCI Banque S.A. French credit institution and insurance brokerage company, with a capital of 100,000,000 EUR Head office: 15 rue d’Uzès – 75002 PARIS SIREN : 306 523 358 R.C.S. Paris – VAT N°: FR95 306523358 – APE code: 6419Z – ORIAS N°: 07 023 704 – www.orias.frMobilize Financial Services is a trademark operated by RCI Banque S.A. Attachment RAPPORT FINANCIER SEMESTRIEL RCI 30-06-2023 ENG

Day: September 4, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice